Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Adam's Take

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

By Adam Feuerstein

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Fish oil pills on pink
Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Fish oil capsules
Adam's Take

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

By Adam Feuerstein

Metastatic Melanoma Cells
Adam's Take

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

By Adam Feuerstein

Sickle Cell meds illo
Adam's Take

Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think

By Adam Feuerstein

Adam's Take

Amgen emerges as new multiple myeloma drug player, threatening Bluebird, Celgene

By Adam Feuerstein

Adam's Take

Answers to biotech’s burning questions for 2018: winners, floppers, and procrastinators

By Adam Feuerstein

Liver illustration
Adam's Take

Can plastic tubes stop livers from failing? Unlikely, but a biotech keeps trying

By Adam Feuerstein

Adam's Take

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

By Adam Feuerstein

Business

Investors are pouring more money into biotech funds, and stocks are responding

By Adam Feuerstein

Adam's Take

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

By Adam Feuerstein

Hepatitis Drugs
Adam's Take

Gilead Sciences’ board is looking for a new CEO. Here’s a list of possible contenders

By Adam Feuerstein

Adam's Take

Gilead’s golden era ends with the executive departures of ‘The Johns’

By Adam Feuerstein

Adam's Take

ResTORbio drug study results weaken under scrutiny

By Adam Feuerstein

Adam's Take

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

By Adam Feuerstein

Celgene
Adam's Take

Celgene is perking up. Here’s what needs to happen for the momentum to continue

By Adam Feuerstein

Adam's Take

Red flags fly over Anavex: What’s stopping the drug maker from enrolling U.S., European patients in trials?

By Adam Feuerstein

Human stem cell BrainStorm
Adam's Take

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

By Adam Feuerstein

Pablo Ross
Adam's Take

Here come the right-to-try profiteers. The FDA is powerless to stop them

By Adam Feuerstein

Red blood cells
Adam's Take

Geron wants J&J to continue a drug development partnership, but new data weaken its case

By Adam Feuerstein

Fatty Liver Drawing
Adam's Take

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

By Adam Feuerstein

Chest X-ray pneumonia
Adam's Take

Proteostasis cystic fibrosis drug disappoints, easing competitor concerns for Vertex Pharma

By Adam Feuerstein

Omeros Bone Marrow
Adam's Take

Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws

By Adam Feuerstein

Adam's Take

A deeply troubled drug company fires its CEO, who then unfires himself. Comedy, chaos ensue

By Adam Feuerstein

Adam's Take

After watching Trump’s drug speech, investors poured big money into biotech funds

By Adam Feuerstein

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy